Cohort of patients of the eps (Entity providing health services) sanitas with rheumatic diseases and covid19

Objectives: It is unclear whether autoimmune diseases increased the risk, worsened the prognosis, or the outcome of patients with SARS-CoV-2 infection. Methods: Observational, cross-sectional study, data collected from a historical cohort of patients with rheumatic diseases between the period of March 2020 and August 2020. Results: 192 patients were included, the majority were women (Women: 68.8%) the most common rheumatic disease was rheumatoid arthritis, followed by Sjogren's syndrome (Table 1). The most frequent associated comorbidity was arterial hypertension (27%), followed by renal disease (8.1%) and diabetes mellitus (8%). The most frequent symptom was headache (92.2%), followed by cough (58.5%), anosmia (44.9%), odynophagia (44.7%) and fever (44.5%). There was some alteration in the measurement of D-dimer, Ferritin, LDH, fibrinogen, troponin, leukocyte count, lymphocytes, platelets, acute phase reactants, transaminases, and creatinine. 36 (18.8%) patients required hospitalization, 10 in the ICU with mechanical ventilatory support. Most of the patients were undergoing treatment with conventional disease-modifying drugs (DMARDcs) (68.8%), 15(8.8%) were undergoing treatment with biological therapy. The main form of contagion suspected was contact with a family member or coworker. Of the total number of patients, 15 (7.8%) died associated with some complication from COVID19 Conclusion: We obtained similar results to international cohorts(1), highlighting important data such as the predominance of rheumatoid arthritis vs other rheumatic disease, the greater use of DMARDcs compared to other therapies and mortality. Likewise, studies should continue to evaluate the behavior of the SARS-COV-2 infection in patients with rheumatic diseases, to understand this infection better.